• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Beremagene geperpavec improves wound healing in dystrophic epidermolysis bullosa

byNhat Hung (Benjamin) LamandKiera Liblik
December 27, 2022
in Chronic Disease, Dermatology
Reading Time: 3 mins read
Video-based behavioral intervention benefits clinical skin examinations
Share on FacebookShare on TwitterShare on LinkedIn

1. Topical gene therapy beremagene geperpavec (B-VEC) was superior to placebo in achieving complete wound healing in patients with dystrophic epidermolysis bullosa (DEB).

2. Pruritus was the most common adverse event associated with B-VEC. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: DEB is a rare genetic skin disease caused by mutations in the COL7A1 gene, which encodes type VII collagen (C7), resulting in extensive and recurrent skin blistering. Long-term complications include an increased risk of squamous-cell carcinoma, infections, and limb deformities. No approved therapies exist for DEB. Gene-based therapies under investigation have been limited by safety concerns, the large size of the COL7A1 gene, and immune reaction to viral vectors. B-VEC is a topical gene therapy based on a replication-defective herpes simplex virus-1 carrying COLV7A1, which could circumvent these limitations. The current study was a phase three trial investigating the efficacy and safety of B-VEC in children and adults with DEB. B-VEC or placebo was administered to a treated wound and healing was compared to an untreated wound. At three and six-month follow-up visits, complete hound healing rates were significantly higher at wound sites treated with B-VEC. Patients in the B-VEC group also reported significant improvement in pain. Pruritis and chills were reported with both B-VEC and placebo. The limitations of this study were the small sample size and the predominance of smaller wounds, which have a shorter healing time. The study findings provide evidence of the efficacy of B-VEC as a corrective therapy for DEB.

Click here to read the study in the NEJM (New England Journal of Medicine)

In-Depth [randomized controlled trial]: The current study was a phase three, double-blind, intra-patient randomized, placebo-controlled trial investigating the efficacy and safety of B-VEC in patients with DEB. Eligible patients were six months of age or older with symptomatic DEB confirmed by genetic testing. Exclusion criteria included participation in trials of B-VEC, concurrent immunotherapy, chemotherapy, or other investigational therapies. In a total of 31 patients, an investigator selected two open wounds of similar size, anatomical region, and appearance, and randomly assigned them 1:1 to be treated weekly with topical B-VEC or placebo for 26 weeks or until wound closure. Wound size and healing were assessed using the Canfield 2D/3D iOS imaging system. The primary endpoint was complete healing at six months. At six months, complete wound healing was observed in 67% of the wounds treated with B-VEC compared to 22% of those treated with placebo (difference, 46 percentage points; 95% Confidence Interval [CI], 24 to 68; p=0.002). Complete wound healing at three months was observed in 71% of the wounds treated with B-VEC, compared to 20% of those treated with placebo (difference, 51 percentage points; 95% CI, 29 to 73; p<0.001). At week 22, the mean change from baseline in pain severity was -0.88 with B-VEC and -0.71 with placebo (adjusted least-squares mean different, -0.61; 95% CI, -1.10 to -0.13), with differences persisting at weeks 24 and 26. Wound closure was also significantly more durable with B-VEC. Adverse events occurred in 58% of patients, the majority of which were mild or moderate and none resulted in treatment discontinuation. Squamous-cell carcinoma occurred in three patients at untreated wound sites. These findings provide evidence to support the use of B-VEC in treating DEB.

RELATED REPORTS

Gene therapy shows sustained benefit in Wiskott–Aldrich syndrome

Atopic dermatitis activity is not associated with cardiovascular risk

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: beremagene geperpavecchronic diseasedermatologydystrophic epidermolysis bullosagene therapytopical gene therapywound healing
Previous Post

Comparison of resuscitative endovascular balloon occlusion of the aorta versus resuscitative thoracotomy for aortic occlusion

Next Post

No significant differences in postoperative complications found between open repair with local anesthesia and laparoscopic repair of inguinal hernias

RelatedReports

A parent and child are depicted holding hands on a seesaw with a DNA helix above them, symbolizing genetic influences.
Chronic Disease

Gene therapy shows sustained benefit in Wiskott–Aldrich syndrome

September 28, 2026
Eczema more prevalent among older adults than previously thought
Cardiology

Atopic dermatitis activity is not associated with cardiovascular risk

April 2, 2026
Medicines in clinical trials collage: a plain white pharmacy bag with a folded top beside capsules and round tablets
All Specialties

Oral remibrutinib hits Phase 3 primary endpoint for inducible hives

March 5, 2026
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Cardiology

2 Minute Medicine: Pharma Roundup – New oral gonorrhea antibiotic Nuzolvence (zoliflodacin), late‑December cardiovascular and oncology drug approvals, first targeted complement inhibitor therapy for HSCT‑TMA (Yartemlea), and antibody‑drug conjugate (ADC) safety concerns with ifinatamab deruxtecan (I‑DXd) [January 2026]

January 26, 2026
Next Post
Hernia repair collage of an engraved belly wall diagram with a small mesh patch, a soft pillow and a pair of walking shoes

No significant differences in postoperative complications found between open repair with local anesthesia and laparoscopic repair of inguinal hernias

Ferric derisomaltose may reduce heart failure-related hospitalizations

Emergency department crowding negative influences outcomes for adults presenting with asthma

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • ADCE-D01 showed a 30% objective response rate in topline phase 1 results for previously treated advanced soft tissue sarcoma
  • Less social media usage is associated with improved internalizing symptoms in high-risk young adults.
  • AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.